Immunotherapy,as an emerging treatment method,has been proven to improve the prognosis of patients with relapsed/refractory B-cell acute lymphoblastic leukemia(B-ALL)and has good application prospects.Immunotherapy,including chimeric antigen receptor T cell immunotherapy(CAR-T)and monoclonal antibodies,has shown great potential for application,and has been approved for marketing.This article summarizes the application of the above two therapies in the treatment of relapsed/refractory B-ALL,and concludes that CAR-T is a kind of personalized immunotherapy,and the selection of ideal targets is an important part of its action.Currently,the ideal targets in clinical studies include CD19,CD22 and CD19/CD22.Monoclonal antibodies,including blinatumomab and inotuzumab ozogamicin,have shown superior therapeutic efficacy for relapsed/refractory B-ALL.Immunotherapy has shown superior therapeutic effects compared to conventional chemotherapy,expanding the selection of treatment options for relapsed/refractory B-ALL.
维普
万方数据